I[n]{.smallcaps} eukaryotic cells, accurate transport of proteins between intracellular compartments is essential to maintain the biochemical identity of each organelle. Proteins trafficking through the secretory pathway use a vesicular transport mechanism in which proteins are actively concentrated into budding vesicles and then delivered in a vectorial manner to subsequent compartments. Efficient sorting of proteins in this system depends upon both selective packaging of proteins into the appropriate vesicles and recognition and fusion of cargo-containing transport vesicles with the correct target organelle.

Formation of many of the vesicle populations that transport cargo through the endocytic and lysosomal pathways requires both the coat protein clathrin and distinct heterotetrameric adaptor protein complexes ([@B36]). While clathrin acts to deform membranes into vesicles, adaptor proteins provide both a binding site for clathrin on the membrane, and act to select cargo for inclusion into vesicles by recognizing sorting signals contained within the cargo proteins themselves ([@B24]; [@B37]). Three distinct adaptor protein complexes, AP-1, AP-2, and AP-3, have been identified in both mammalian cells and in yeast and are thought to direct transport of cargo proteins into the endocytic/lysosomal pathways ([@B30]; [@B44]; [@B13]; [@B41]) by recognition of two main classes of sorting signals; tyrosine- ([@B8]) and di-leucine--based ([@B23]; [@B24]) sorting motifs. In mammalian cells, AP-1 and AP-2 are associated with budding clathrin-coated vesicles at the TGN and the plasma membrane, respectively, although assigning sorting function to these proteins in yeast has been difficult as deletions of these genes do not result in detectable protein sorting phenotypes ([@B36]). AP-3 has been assigned a sorting function in the process of pigment deposition in *Drosophila* ([@B41]) and cargo selective transport of proteins to the vacuole in yeast ([@B10]; [@B45]).

Once vesicles have budded from a donor membrane, specific cognate interactions between SNAP receptor (SNARE)^1^ proteins, which are found on both vesicle (v)- SNARE and target (t)-SNARE membranes, are thought to provide the targeting specificity required for a transport vesicle to dock and fuse with the appropriate acceptor organelle ([@B6]; [@B5]; [@B42]). At each intracellular compartment, SNAREs act with members of several other protein families, including compartment-specific Sec1p and Rab proteins and the general factors *N*-ethylmaleimide--sensitive factor (NSF) (Sec18p) and soluble NSF attachment protein (SNAP) (Sec17p), which together are thought to regulate the formation and/or activity of SNARE complexes (for review see [@B27]; [@B38]). In accordance with their targeting function, t-SNAREs are associated for the most part with individual compartments and become, in effect, markers for that compartment. Thus, t-SNAREs represent a large family of related proteins, each of which must be sorted to a distinct cellular location to maintain accurate intracellular protein trafficking.

In yeast, protein transport to the vacuole has proven to be a powerful model system for the study of protein sorting, as many of the required components (i.e., adaptor proteins, SNAREs, Sec1, and Rab proteins) are evolutionarily conserved ([@B5]; [@B43]). The characterization of a large collection of [v]{.ul}acuolar [p]{.ul}rotein [s]{.ul}orting (*VPS*) genes has revealed two distinct routes by which proteins traffic from the TGN to the vacuole. These routes can be distinguished in temperature-sensitive mutants of transport components that display differential effects on the transport of two vacuolar hydrolases, carboxypeptidase Y (CPY) and alkaline phosphatase (ALP). Many vacuolar resident proteins, such as CPY, are delivered to the vacuole through a well defined route that requires the function of the *VPS* genes, one of which encodes the endosomal t-SNARE, Pep12p ([@B4]). In contrast, the vacuolar integral membrane protein ALP is transported to the vacuole in a manner that is independent of *PEP12* ([@B11]), and is therefore presumed to bypass this endosomal compartment. Instead, ALP transport to the vacuole follows an AP-3 adaptor protein--dependent pathway ([@B10]; [@B45]). Vam3p, the vacuolar t-SNARE, is required for delivery of both CPY and ALP to the vacuole, indicating that these distinct pathways ultimately converge at this docking site ([@B12]). Interestingly, localization studies indicate that Vam3p may also be transported to the vacuole via the ALP pathway, suggesting that it too may bypass the endosomal compartment defined by Pep12p ([@B11]; [@B31]).

Although Vam3p and Pep12p perform analogous biochemical t-SNARE functions, these genes clearly have distinct sites of action ([@B4]; [@B7]; [@B12]). Surprisingly, however, overexpression of *VAM3* can compensate for the loss of *PEP12* function ([@B12]; [@B16]), suggesting that under some conditions, Vam3p can substitute for Pep12p. We designed a random genetic screen to define the sequence determinants in Vam3p that allow it to replace Pep12p. This screen specifically identified a small region within the Vam3p sequence (NEQSPLL), which is similar to a region of the ALP cytosolic tail that contains a di-leucine sequence required for proper sorting ([@B11]; [@B47]). Furthermore, many of the mutations within the presumptive Vam3p sorting determinant caused mislocalization of Vam3p. Together, these results suggest that the Vam3p t-SNARE is likely to be transported to the vacuole through the AP-3/ALP pathway via recognition of an acidic di-leucine sorting signal. Thus, trafficking of Vam3p to the vacuole through the AP-3 pathway appears to play an important role in restricting its site of function and regulating its association with other components of the transport machinery.

Materials and Methods {#MaterialsMethods}
=====================

Strains and Media
-----------------

*Saccharomyces cerevisiae* strains used for these studies are listed in Table [I](#TI){ref-type="table"}. Yeast strains were grown in standard yeast extract-peptone-dextrose (YPD) or synthetic medium (YNB) supplemented with essential amino acids. Standard bacterial medium, containing 100 μg/ml ampicillin for plasmid selection, was used to propagate *Escherichia coli*. Transformation of *S*. *cerevisiae* was done by the lithium acetate method ([@B21]). *E*. *coli* transformations were done by the method of [@B17].

Plasmid Construction and Nucleic Acid Manipulations
---------------------------------------------------

Restriction and modification enzymes were purchased from Boehringer Mannheim (Indianapolis, IN), New England Biolabs (Beverly, MA), or U.S. Biochemical Corporation (Cleveland, OH). Alleles of *vam3* were constructed in pVAM3.414 and were subcloned into pRS416 by excising the NotI--XhoI fragment and ligating into NotI--XhoI-digested pRS416 ([@B40]). For construction of NH~2~-terminal green fluorescent protein (GFP) fusion constructs, a 900-bp fragment containing the *VAM3* open reading frame (ORF) was amplified from either wild-type or mutant *VAM3* template using primers that induced an in-frame BglII site at the start codon and an EcoRI site after the stop codon. BglII--EcoRI- digested PCR product was then ligated into BamHI--EcoRI-digested pGOGFP fusion vector ([@B10]). Plasmids pVAM3.414 and pVAM3.424 were described previously ([@B12]).

Alleles of *VAM3* were constructed by PCR based mutagenesis ([@B26]). Primers complimentary to chromosomal sequences immediately adjacent to the start and stop codons of *VAM3* were used to amplify a 900-bp fragment (containing the entirety of the *VAM3* ORF) under limiting dATP, dTTP, or dGTP conditions (20 μM) in separate reactions. The resulting PCR products were precipitated in 95% ethanol, combined, and then gel purified. A gapped plasmid was generated by digesting pVAM3.414 with BsmI and isolating the vector by gel purification. The mutagenized PCR product and gapped plasmid were co-transformed into CBY31 cells and transformants in which homologous recombination resulted in integration of mutagenized PCR product were selected by amino acid prototrophy. Transformants were replica plated onto YPD containing 50 μg/ml geneticin (Gibco Laboratories, Grand Island, NY) and grown at 30°C for 2 d. Presumptive mutant colonies were picked, retested, and then plasmid linkage of the G418 resistance phenotype was confirmed by retransformation of isolated plasmids into CBY31 cells.

Site-directed mutagenesis of Q156 was performed by amplifying the *VAM3* locus by PCR using mutagenic primers in a gene SOE ([s]{.ul}plicing by [o]{.ul}verlap [e]{.ul}xtension) reaction. Complimentary primers containing the appropriate mutation were used in conjunction with primers complimentary to sequences ∼300 bp both 5′ and 3′ of the *VAM3* ORF for the initial amplification. A secondary amplification using the initial PCR products as template was performed using only the outside primers to amplify the full-length *vam3* mutant. The resultant PCR product was cloned into TOPO TA vector (Invitrogen Corp., Carlsbad, CA). The EcoRI fragment of the TA clones was excised and ligated into EcoRI-digested pRS414 vector for yeast expression. The mutation introduced a unique SacI restriction site and positive insert-containing clones were confirmed to be point mutants by digestion with SacI.

Plasmids isolated from the G418 resistance screen were purified from *E*. *coli* using miniprep spin columns (QIAGEN Inc., Valencia, CA). Resultant plasmids were denatured, hybridized to sequencing primers, and then subjected to dideoxy chain termination sequence analysis using the Sequenase enzymes and protocol (U.S. Biochemical Corporation).

Metabolic Labeling and Immunoprecipitation
------------------------------------------

To analyze the transport of vacuolar proteins, yeast cells were grown at 26°C in synthetic medium supplemented with amino acids to an OD~600~ of 0.5--1.0. Cells were harvested and converted to spheroplasts as described previously ([@B29]). Spheroplasts were resuspended at a concentration of 3 OD~600~/ml in synthetic medium containing amino acids and supplemented with 100 μg/ml α2-macroglobulin and 1 mg/ml BSA to stabilize secreted proteins. Cultures were pre-incubated at the appropriate experimental temperature for 5 min, and then labeled with 60 μCi \[^35^S\]cysteine/methionine per ml of cell suspension. After labeling, cultures were chased with the addition of methionine, cysteine, yeast extract, and glucose to a final concentration of 5 mM, 1 mM, 0.4%, and 0.2%, respectively. After appropriate chase periods, samples were harvested and precipitated by addition of TCA (10% final concentration). For analysis of CPY in whole cells, metabolic labelings were done in a similar manner except BSA and α2-macroglobulin were excluded from the labeling medium. Whole cells lysates were generated by glass bead disruption in urea buffer (50 mM Tris, pH 7.5, 1 mM EDTA, 1% SDS, and 6 M urea). In both spheroplast and whole cell experiments, immunoprecipitated proteins were resolved by SDS-PAGE and analyzed by autoradiography. Antibodies to CPY and Pep12p have been previously described ([@B22]; [@B4]). mAbs to Vph1p and ALP were purchased from Molecular Probes (Eugene, OR).

Subcellular Fractionation and Gradient Analysis
-----------------------------------------------

For intracellular localization of proteins, cells were converted to spheroplasts and lysed in Hepes KOAc lysis buffer containing protease inhibitors to the following final concentrations: 20 μg/ml PMSF; 5 μg/ml antipain; 1 μg/ml aprotinin; 0.5 μg/ml leupeptin; 0.7 μg/ml pepstatin; and 10 μg/ml α2-macroglobulin ([@B15]). After a 5-min clearing spin at 300 *g*, the spheroplast lysate was sequentially centrifuged at 13,000 *g* (15 min) and 100,000 *g* (60 min) to generate both high and low speed pellet and supernatant fractions. Resulting samples were TCA precipitated and analyzed by immunoblotting and ECL detection as described previously ([@B1]). Gradient Accudenz (Accurate Chemical and Scientific Corporation, Westbury, NY) solutions were prepared (wt/vol) in 10 mM Hepes KOAc, pH 7.6, with protease inhibitors. The gradient was generated using the following Accudenz concentration steps from bottom to top: 0.5 ml 60%; 1 ml 50%; 1 ml 43%; 1 ml 37%; 1 ml 31%; 1 ml 27%; 1 ml 23%; 1 ml 20%; 1 ml 17%; 1 ml 13%; 1 ml 7%. Gradient analysis was performed on 15 OD~600~equivalents of cleared spheroplast lysate in a volume of 1.5 ml loaded on top of the gradient. The gradient was subjected to centrifugation at 4°C in a Beckman SW41 rotor at 170,000 *g* for 20 h. 12 fractions were harvested manually from the top of the gradient, proteins were TCA precipitated and analyzed by immunoblotting. Quantitation of proteins on gels was done by densitometry using NIH Image.

Fluorescence Microscopy
-----------------------

To examine vacuolar and endocytic structures in live yeast cells, FM4-64 (Molecular Probes) labeling was done as previously described ([@B46]) except that the labeling was done at a concentration of 16 μM FM4-64 at 26°C for 1 h and the cells were chased for a period of 1.5 h. Visualization of FM4-64 and GFP was done either by confocal microscopy or fluorescence microscopy using rhodamine and fluorescein filters, respectively.

Results {#Results}
=======

Identification of VAM3 Mutants Capable of Substituting for PEP12
----------------------------------------------------------------

Vam3p and Pep12p are two homologous yeast t-SNARE proteins involved in protein transport to the vacuole in yeast. Although Vam3p and Pep12p have clearly distinguishable functions (i.e., Pep12p acts at the endosome and Vam3p acts at the vacuole) (Fig. [1](#F1){ref-type="fig"} *A*), when overexpressed, these proteins are able to partially substitute for one another ([@B12]; [@B16]). This suggests that the specificity of Vam3p and Pep12p functions may be dependent on interactions with other compartment-specific transport components (Sec1 homologues, Rab proteins). Based on this observation, we reasoned that mutations in Vam3p that allow it to substitute for Pep12p might uncover domains required for localization and/or specific protein--protein interactions of Vam3p with Pep12p-specific transport components.

Several *vps* mutants, including *pep12Δ*, are hypersensitive to geneticin (G418), an aminoglycoside antibiotic related to gentamicin (Fig. [1](#F1){ref-type="fig"} *B*). The mechanism of this hypersensitivity is unknown but for *pep12Δ* mutants it appears to correlate with extent of vacuolar protein sorting defects. For example, overexpression of *VAM3* from a multi-copy vector in *pep12Δ* cells restored viability to cells grown on media containing 50 μg/ml G418, while *VAM3* expressed at single copy (which does not improve CPY sorting when expressed in *pep12Δ* cells) did not rescue the growth defects of *pep12Δ* cells on media containing 50 μg/ml G418 (Fig. [1](#F1){ref-type="fig"} *B*). Therefore, selection by growth on G418-containing media presented an easily scoreable phenotype that could be used to select for *vam3* mutants capable of suppressing the growth defects of *pep12Δ* cells on media containing G418.

The entire *VAM3* ORF was randomly mutagenized by error-prone PCR-mediated mutagenesis and then co-transformed with a gapped, single-copy plasmid into *pep12Δ* mutant cells ([@B26]). Transformants were replica plated onto media containing 50 μg/ml G418, and viable colonies were selected. Approximately 10,000 colonies were screened, and \>100 *vam3* mutant clones that had acquired the ability to suppress the growth defects of *pep12Δ* cells at 50 μg/ml G418 were recovered. We selected ∼50 representative clones that grew well at 50 μg/ml G418 and rescued plasmids from these strains. 30 mutants that showed plasmid linkage for the G418 resistance phenotype were selected for further analysis. As a secondary screen, we tested the growth of these mutants at elevated concentrations of G418. This criteria allowed us to separate the mutants into two general classes: (*1*) strong mutants that conferred resistance to 100 μg/ml G418, and (*2*) weaker mutants that conferred resistance to only 50 μg/ml G418.

Sequence analysis revealed that each of the 30 mutants recovered in this screen contained at least one mutation within a 7--amino acid region of Vam3p, corresponding to amino acids 154--160 (Fig. [2](#F2){ref-type="fig"}). This sequence of Vam3p lies approximately in the middle of the protein, between the two coiled-coil domains, and it is distanced well away from the transmembrane domain in a region that does not exhibit high sequence similarity to Pep12p. However, the sequence closely resembles a region in the cytosolic tail of ALP that has been shown to be necessary for transport of ALP through the AP-3--dependent pathway to the vacuole ([@B11]; [@B47]). These characteristics, together with the presence of a leucine pair at positions 159--160, suggested that this region may represent a di-leucine--type sorting signal in Vam3p.

Somewhat surprisingly, the mutations in the 30 plasmids represented only seven separate single mutations in the following five residues: asparagine 154, glutamate 155, serine 157, leucine 159, and leucine 160 (Fig. [2](#F2){ref-type="fig"}). No other amino acid substitutions in Vam3p were found outside of this region. The recovery of multiple identical mutants in each residue indicates that the screen was near saturation and that the most relevant residues in Vam3p that confer suppression of the *pep12Δ* mutation had likely been mutated. The mutants that conferred the highest level of G418 resistance (100 μg/ml) were glutamic acid 155 (at −4 relative to the di-leucine pair) to lysine (*vam3* ^E155K^), and leucine 160 to proline (*vam3* ^L160P^). However, when these same residues were mutated to either glycine (*vam3* ^E155G^) or glutamate (*vam3* ^L160Q^), respectively, the cells grew only at the lower concentration of G418 (50 μg/ml). Independently isolated clones containing mutations in asparagine 154 at the −5 position from the di-leucine (*vam3* ^N154K^), serine 157 at the −2 position (*vam3* ^S157G^), and leucine 159 (*vam3* ^L159S^) also resulted in maximum G418 resistance at 50 μg/ml G418 (Fig. [2](#F2){ref-type="fig"}).

The ALP cytoplasmic tail sequence and the Vam3p sequence both contain a conserved glutamine at the −3 position (Fig. [2](#F2){ref-type="fig"}). Since glutamine mutants were not recovered in the G418 selection, we wanted to determine whether it was required for the function of the Vam3p domain. Using site-directed mutagenesis, we changed the glutamine 156 to leucine (*vam3* ^Q156L^), transformed the mutant into *pep12Δ* cells and assayed for G418 resistance. The *vam3* ^Q156L^ mutant did not confer G418 resistance to *pep12Δ* cells. However, when the *vam3* ^Q156L^ point mutation was transformed into *vam3Δ* cells, it complemented both the morphological defects and the CPY sorting defects of the *vam3Δ* cells (data not shown), indicating that a full-length, functional protein was still produced. Therefore, the glutamine at the −3 position of the Vam3p motif is not required for normal Vam3p function.

Vam3p Mutants Partially Substitute for Pep12p Function in Vacuolar Protein Sorting
----------------------------------------------------------------------------------

To confirm that the G418 resistance phenotype used to isolate *vam3* mutants correlated with suppression of CPY defects of *pep12Δ* cells harboring these mutant forms of *VAM3* we examined CPY sorting by pulse-chase/immunoprecipitation analysis. As expected, in *pep12Δ* cells CPY was recovered almost exclusively as the Golgi-modified p2 form, consistent with severe defects in Golgi-to-endosome transport. Similarly, *pep12Δ* cells expressing *VAM3* from a single-copy plasmid did not show any significant improvement in CPY sorting. However, in all cases, *pep12Δ* cells expressing *vam3* mutants from a single-copy plasmid that conferred G418 resistance also exhibited improved CPY sorting. Moreover, efficiency of CPY sorting in *pep12Δ* cells harboring the various *vam3* mutants correlated with degree of G418 resistance as mutants that exhibited resistance to high concentrations of G418 sorted and matured more CPY than mutants resistant to only lower (50 μg/ml) G418 concentrations. For example, *pep12Δ* cells expressing the *vam3* ^N154I^ mutant, which is resistant to G418 concentrations up to 50 μg/ml, converted ∼50% of p2 CPY to the mature form, whereas *pep12Δ* cells expressing the *vam3* ^L160P^ mutant, which is resistant to 100 μg/ml G418, matured ∼80% of CPY (Fig. [3](#F3){ref-type="fig"} *A*).

As Vam3p requires AP-3 for its normal transport and localization to the vacuole, disruption of the AP-3 pathway may mimic the effects of the Vam3p sorting signal mutations. To examine this possibility, we analyzed CPY sorting in both *pep12Δ* cells and *apm3Δpep12Δ* double mutant cells, each expressing an additional copy of wild-type *VAM3* to mimic the conditions of the mutant screen. In contrast to *pep12Δ* cells containing wild-type *VAM3*, in which CPY is blocked exclusively in the p2 form, ∼80% of CPY was converted to the mature vacuolar form in *apm3Δpep12Δ* double mutant cells (Fig. [3](#F3){ref-type="fig"} *A*). This was remarkably similar to results obtained for Vam3p mutants such as *vam3* ^L160P^ expressed in *pep12Δ* cells, and suggests that these mutations allow CPY maturation because they prevent normal recognition of Vam3p by the AP-3 adaptor complex and result in missorting of Vam3p to the pre-vacuolar endosome where it can partially substitute for Pep12p.

VAM3 Mutants Still Maintain Vam3p Function
------------------------------------------

We were interested in determining whether the *vam3* mutants were capable of normal Vam3p t-SNARE function at the vacuole. Since the screen was performed in a strain containing a wild-type *VAM3* gene, it was possible that mutations allowing for suppression of *pep12Δ* sorting defects would also result in loss of the ability of these proteins to function as Vam3p. Therefore, we examined CPY sorting by pulse-chase analysis in *vam3Δ* cells transformed with the mutants recovered from the screen. As expected, *vam3Δ* cells accumulated only p2 precursor CPY, indicating that transport of CPY to the vacuole was blocked. However, *vam3* mutants that resulted in both strong (*vam3* ^L106P^) and weak (*vam3* ^N154I^) suppression of *pep12Δ* mutant phenotypes completely complemented the CPY sorting defects of the *vam3Δ* strain (Fig. [3](#F3){ref-type="fig"} *B*), indicating that although these mutants can substitute for the Pep12p t-SNARE, they also retain Vam3p t-SNARE function. These results suggest that the mutant Vam3 proteins must at least partially localize to the vacuole, the normal site of Vam3p function.

Mutant Vam3 Proteins Are Missorted into the CPY Pathway
-------------------------------------------------------

The ability of the *vam3* mutants to suppress *pep12Δ* vacuolar protein sorting defects suggests that mutant Vam3 proteins are at least partially localized to the pre-vacuolar endosome, the site of Pep12p function. To examine the localization of the Vam3 mutant proteins, we fractionated cells and examined the distribution of the Vam3 mutant proteins relative to wild-type Vam3p by differential centrifugation. Vam3p fractionates exclusively in a low speed (P13) pellet fraction by differential centrifugation, which is consistent with its vacuolar localization ([@B12]). However, the mutant forms of Vam3p fractionated differently than the wild-type protein, with a significant portion of the proteins localized to a high speed P100 pellet, (data not shown) which indicated that at least a portion of the mutant proteins localized to a non-vacuolar fraction. Although the P13 fraction is enriched in vacuoles, other compartments also fractionate in the P13. For example, the endosomal t-SNARE Pep12p typically exhibits a 40% P13/60% P100 fractionation pattern, even though this protein is not localized to the vacuole ([@B4]). To further resolve vacuoles away from other P13 material, *vam3Δ* cells harboring either single-copy wild-type *VAM3* or the *vam3* ^L160P^ mutant were analyzed by equilibrium density gradient fractionation. Cleared spheroplast lysates were applied to the top of Accudenz step gradients, which were then centrifuged to equilibrium. Fractions were collected from the top of the gradient and analyzed for the presence of Vam3p, Vph1p, and the endosomal t-SNARE, Pep12p. In both gradients, Vph1p fractionated primarily in the low density fractions (1--4) of the gradient, as is typical for vacuolar membrane proteins ([@B12]) (Fig. [4](#F4){ref-type="fig"} *A*). In contrast, Pep12p fractionated exclusively in more dense regions of the gradient (fractions 5--7), indicating that distinct separation of vacuoles and endosomes was achieved in these gradients (Fig. [4](#F4){ref-type="fig"} *B*). As expected, wild-type Vam3p primarily co-fractionated with Vph1p in the first four fractions of the gradient. However, while a small percentage of Vam3p^L160P^ also fractionated in the top (vacuolar) region of the gradient, the majority of the mutant Vam3 protein (∼80%) was recovered in more dense fractions (5--7), which also contained Pep12p (Fig. [4](#F4){ref-type="fig"} *B*). Thus, while some Vam3p^L160P^ is localized to the vacuole, most of the protein appears to reside in a non-vacuolar compartment that co-fractionates with Pep12p-containing endosomes.

The cell fractionation data suggested that a significant portion of the mutant Vam3 proteins were mislocalized to compartments other than the vacuole. To visualize the compartments in which the mislocalized proteins were residing, we constructed GFP fusions with wild-type and mutant Vam3 proteins. We transformed the plasmid constructs into *vam3Δ* cells and examined the cells by fluorescence microscopy. Both the wild-type and mutant Vam3 fusion proteins complemented the protein sorting (data not shown) and morphology defects associated with *vam3Δ* cells (Fig. [5](#F5){ref-type="fig"} *A*) and thus functioned as the native proteins. Consistent with the previous localization studies, wild-type GFP-Vam3 fusion protein localized almost exclusively to vacuolar membranes (Fig. [5](#F5){ref-type="fig"} *A*). While GFP-Vam3^L160P^ still accumulated in vacuolar membranes, a large portion of the protein was also seen in tubular and punctate structures throughout the cell (Fig. [5](#F5){ref-type="fig"} *A*). GFP fusion proteins of the other Vam3p mutants also behaved in a similar manner (data not shown), indicating that these mutant proteins accumulate in non-vacuolar structures.

Class E *vps* mutants contain large aberrant endosomal structures (class E compartments), which accumulate both biosynthetic cargoes (e.g., CPY) as well as endocytic cargoes (e.g., the lipophilic dye FM4-64) ([@B35]). However, proteins that travel through the AP-3--dependent pathway (e.g., ALP, Vam3p) do not accumulate in the class E compartment, as this pathway bypasses the endosome ([@B1]; [@B31]). Unlike wild-type Vam3p, if the mutant Vam3 proteins travel through the CPY pathway to the vacuole, they should accumulate in the class E compartment. We transformed class E mutant *vps24Δ* cells with plasmids encoding either GFP-Vam3 or GFP-Vam3^L160P^ mutant fusion protein, labeled the cells with FM4-64, and examined the cells for both markers by fluorescence microscopy. Wild-type GFP-Vam3 fusion protein accumulated primarily on vacuolar membranes and was excluded from the class E compartment (Fig. [5](#F5){ref-type="fig"} *B*). In contrast, a large percentage of the cells expressing GFP-Vam3p^L160P^ displayed brightly fluorescent signal in a perivacuolar compartment, in addition to a lower intensity fluorescent signal on the vacuolar membrane (Fig. [5](#F5){ref-type="fig"} *B*). FM4-64 counterstaining showed that this perivacuolar compartment was coincident with the class E compartment. GFP fusion proteins made with the other Vam3p mutants also accumulated in the E compartment in a similar manner (data not shown), indicating that mislocalization through the CPY pathway occurred in all of the mutants. Together, these localization data provide compelling evidence that the mutant proteins do not traffic to the vacuole through the AP-3--dependent pathway but instead transit the CPY pathway and accumulate in pre-vacuolar compartments.

Discussion {#Discussion}
==========

We have described a novel genetic screen for mutations in the vacuolar t-SNARE Vam3p that allow it to functionally replace the endosomal t-SNARE, Pep12p. SNARE proteins would appear to be one of the most important cargoes to be selectively sorted, as they represent a core component of the vesicle docking/fusion machinery. The correct sorting of many other cargo proteins depends on proper localization of these t-SNARE molecules. Here we provide the first identification of a defined sorting signal in a t-SNARE protein. Previous studies have indicated that both transmembrane and cytosolic domains of t-SNAREs contain information that influences their localization ([@B3]; [@B34]). However, these studies did not define primary sequence sorting signals, nor did they identify specific transport components that may be involved in the sorting of these proteins (e.g., sorting receptors). This study provides significant, in vivo evidence that Vam3p, like ALP, is sorted by recognition of an acidic di-leucine motif through an AP-3--dependent pathway. Furthermore, disruption of the di-leucine sorting signal in Vam3p results in mislocalization of Vam3p to the pre-vacuolar endosome where it functionally substitutes for the endosomal t-SNARE Pep12p. These results suggest that the trafficking route of a SNARE acts to restrict its site of function and that localization plays an important role in determining the functional specificity of a given SNARE protein. Therefore, trafficking of Vam3p through the AP-3/ALP pathway plays a vital role in maintaining the unique composition and function of the vacuole. Furthermore, these observations provide insight into the requirement for the AP-3--dependent alternative Golgi-to-vacuole transport pathway.

Vam3p Contains a Putative Di-leucine--type Sorting Signal That Directs It into the ALP Pathway
----------------------------------------------------------------------------------------------

The only known cargo of the AP-3--dependent sorting pathway to the vacuole in yeast is ALP ([@B10]; [@B45]). However, several lines of evidence suggest that Vam3p also traffics through this route. First, Vam3p localizes to the vacuole in a manner independent of the function of Pep12p ([@B11]) and the class E Vps proteins Vps4p and Vps27p, and is specifically excluded from the class E compartment ([@B1]; [@B31]), suggesting that it does not transit through the pre-vacuolar endosome in the CPY pathway en route to the vacuole. Furthermore, in an AP-3 mutant, Vam3p is mislocalized to a non-vacuolar compartment in the same manner as ALP ([@B10]). A di-leucine sorting signal in the cytosolic tail of ALP has been shown to be necessary for AP-3--dependent sorting of ALP to the vacuole ([@B11]; [@B47]). While Vam3p contains multiple putative di-leucine sequences within its cytoplasmic domain, we have found through a random mutagenesis screen that disruption of only one of the potential di-leucine signals in Vam3p alters its trafficking route and allows it to function at a non-vacuolar compartment. Furthermore, deletion of AP-3 complex components results in similar phenotypes as disruption of the di-leucine sequence of Vam3p. Together, these data strongly suggest that Vam3p traffics through the AP-3--dependent ALP pathway via recognition of a di-leucine motif. It was recently shown that di-leucine sorting signals in the mammalian proteins LIMP II, a lysosomal membrane protein, and tyrosinase, a melanosomal membrane protein that functions in melanin synthesis, bind to AP-3--enriched fractions in an in vitro surface plasmon resonance (SPR) assay, which is suggestive of direct interactions between di-leucine motifs and AP-3 ([@B19]). Our work provides strong in vivo evidence that di-leucine motifs are required for directing cargo into the AP-3--mediated transport pathway in yeast.

Vam3p Mutants Reveal a Role for Additional Residues in the Di-leucine Motif
---------------------------------------------------------------------------

Random mutagenesis of Vam3p identified a small 7--amino acid region in the middle of the cytoplasmic domain of Vam3p that includes a leucine pair as well as several amino acids just to the NH~2~-terminal side of the di-leucine sequence. Because di-leucine sorting signals have been implicated in endocytosis from the plasma membrane ([@B23]; [@B32]) and also have been shown to be capable of direct binding to both AP-1 and AP-2 in vitro ([@B18]; [@B14]; [@B33]), it is likely that only a subset of di-leucine motifs interact with AP-3. Mutations in the glutamate at position −4 relative to the leucine pair in Vam3p resulted in particularly strong phenotypes, comparable to mutations in either of the leucine residues. These results are consistent with in vitro studies that have shown that mutation of the acidic residues in the di-leucine sorting signals in LIMP II and tyrosinase abrogate binding to AP-3--enriched fractions ([@B19]). However, acidic residues in addition to the di-leucine pair do not seem to be sufficient to direct AP-3 binding, since many mammalian proteins containing similar sequences do not seem to be sorted through AP-3--dependent pathways ([@B19]). Our analysis has identified several additional residues that also contribute to the function of the di-leucine motif. In addition to the acidic residue at −4 and the leucine pair, the Vam3p motif requires an upstream polar residue at −5 and a hydrophilic amino acid at the −3 position for optimal sorting activity. In fact, the sorting determinant in ALP contains conserved residues at the same positions to each of the additional residues that were mutated in Vam3p (Fig. [6](#F6){ref-type="fig"}).

Similar sequence characteristics can also be found in many of the other candidate AP-3 cargoes that have been identified in mammalian systems. Melanosomal resident enzymes have been implicated as cargo for AP-3--directed sorting, as mutant mice in both AP-3 components and melanosomal proteins result in similar aberrant coat color phenotypes, suggesting that these pigmentation defects may be due to improper sorting of proteins to melanosomes ([@B28]). Di-leucine motifs in many melanosomal proteins also contain a conserved hydrophilic amino acid at the −3 position (Fig. [6](#F6){ref-type="fig"}). In addition, mutation of residues at the same positions in proteins such as invariant chain, which do not bind to AP-3, have been shown to have no effect on the transport of these proteins ([@B25]; [@B32]; [@B19]). Both the Vam3p di-leucine sequence and the di-leucine sequences in many of the other potential AP-3 cargoes contain a conserved proline at the −1 position. However, we did not recover mutations in this residue and it is not conserved in the ALP sequence, suggesting that this proline may not be required for the function di-leucine sorting signals, at least in yeast. Together, these data point to a conserved sorting motif for most AP-3--dependent cargoes and a common mechanism for the recognition and packaging of these cargoes. Further mutational analysis of conserved amino acids in other vacuolar/lysosomal and melanosomal protein sequences will confirm the importance of these residues in AP-3--directed sorting. Sequence search algorithms derived from such analysis may also be useful in identifying new potential cargo proteins in the AP-3 pathway and may help to further define the pathway\'s biological significance.

Disruption of the Vam3p Di-leucine Motif Causes Mislocalization of Vam3p into the CPY Pathway
---------------------------------------------------------------------------------------------

The CPY pathway seems to be the "default" route to the vacuole, as no sorting signals required for transport of membrane proteins into this pathway have been defined and proteins that normally transit through this pathway can be diverted into other pathways by the addition of positive sorting signals ([@B11]). Furthermore, overexpression of either ALP or Vam3p results in their overflow into the CPY pathway, consistent with saturation of the signal recognition/packaging machinery in the AP-3 pathway ([@B11]; [@B12]). We have shown that disruption of the di-leucine sorting signal in Vam3p results in the mislocalization of the protein into the CPY pathway. It has been previously shown that Vam3p is missorted in AP-3 mutants and co-fractionates with late Golgi and endosomal markers ([@B10]). Consistent with these observations, we found that Vam3p sorting signal mutants accumulate in a Pep12p-containing intermediate compartment, most likely a pre-vacuolar endosome. The following observations support this model: (*a*) the Vam3 mutant proteins are capable of suppressing the defects of *pep12Δ* cells, which argues that the proteins are reaching a compartment where Pep12p normally operates, (*b*) the mutant proteins co-fractionate with Pep12p and are in a distinct location from vacuolar markers in fractionation experiments and finally, and (*c*) the accumulation of the Vam3 mutant proteins in a class E mutant endosome implies that the proteins are not being specifically retained in the Golgi complex but instead are being transported forward at least until the class E block is initiated, which is thought to be at the point of exit from the endosomal compartment ([@B1]). Together, these data suggest that a large pool of the Vam3 mutant proteins reside at steady state in a pre-vacuolar endosome.

The localization data also indicate that only a minor fraction of the mutant proteins arrive at the vacuole (∼20%), and thus, that transport of Vam3p to the vacuole through the CPY pathway is inefficient. It is therefore possible that mechanisms may exist which retain the majority of Vam3 mutant protein in a stable, pre-vacuolar compartment. In wild-type cells, Pep12p is also retained within the pre-vacuolar endosomal compartment, possibly by a similar mechanism. Perhaps within their highly conserved primary sequence, Pep12p and Vam3p contain retention motifs that maintain their localization in the endosome, either by preventing forward transport or through recycling. Alternately, interactions with compartment-specific SNARE accessory proteins that function at the pre-vacuolar endosome, such as Vps45p, Vps21p, or Vac1p ([@B9]; [@B20]; [@B7]), could act to retain both Pep12p and the mutant Vam3 proteins in the endosome. This would be consistent with our previous findings that Vam3p-specific suppression of *pep12Δ* requires expression of endosomal transport components ([@B12]).

AP-3--mediated Localization Restricts the Function of the Vam3p t-SNARE Protein
-------------------------------------------------------------------------------

It has previously been shown that overexpression of *VAM3* can partially suppress the vacuolar protein sorting defects of a *pep12* null mutant and that this activity may be dependent on mislocalization of Vam3p to the Pep12p compartment ([@B12]; [@B16]). Our results presented here confirm that mislocalization of Vam3p allows it to efficiently substitute for Pep12p. While we can not rule out that Vam3 mutant proteins have increased affinity for Pep12p-specific components (e.g., Vps45p), the data are most consistent with a model in which these mutations result in quantitative missorting of Vam3p to the pre-vacuolar endosome where it can efficiently substitute for Pep12p.

The finding that in the absence of a functional di-leucine motif, Vam3p both localizes and functions at an earlier step in the CPY pathway has several interesting implications for the function of t-SNARE proteins. Both Vam3p and Pep12p act in what appear to be classical SNARE- mediated transport steps. They both require specific accessory proteins such as Rab and Sec1 homologues, as well as the general cytosolic fusion machinery, including Sec18p (NSF), for their activity ([@B7]; [@B12]; [@B39]). By simply driving Vam3p into a different biosynthetic transport pathway, as may be accomplished either by Vam3p overexpression, disruption of the Vam3p sorting signal, or by disruption of the sorting machinery itself, Vam3p is able to function at a different compartment in the Golgi-to-vacuole transport pathway. These results suggest that a major distinguishing characteristic between Pep12p and Vam3p is their biosynthetic transport route and localization. Current models for SNARE function postulate that cognate interactions between t- and v-SNAREs define the primary specificity of each transport step. However, our observations are most consistent with a model in which SNARE proteins are much more promiscuous in their interactions with accessory proteins and, when localized improperly, are able to partially function at alternate sites. For example, although Vam3p normally acts in conjunction with the vacuolar Sec1 homologue, Vps33p, the suppression of *pep12Δ* by *VAM3* overexpression also requires Vps45p, the endosomal Sec1 homologue ([@B12]). In this case, Vam3p appears to use the docking and fusion machinery of the endosome rather than recruiting these accessory proteins from the vacuole. Clearly then, t-SNARE proteins do not define the sole component of specificity of vesicular transport, and other compartment specific proteins must also be present and act with the t-SNARE to accomplish this goal. It remains to be determined which proteins, or combination of proteins are ultimately responsible for transport specificity, but it seems likely that a set of complex interactions at each transport step may be required for accurate vesicular transport.
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ALP

:   alkaline phosphatase

CPY

:   carboxypeptidase Y

GFP

:   green fluorescent protein

NSF

:   *N*-ethylmaleimide--sensitive factor

ORF

:   open reading frame

SNAP

:   soluble NSF attachment protein

SNARE

:   SNAP receptor

VPS

:   vacuolar protein sorting
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S. cerevisiae Strains Used in This Study

  Strain       Genotype                                                              Reference or source
  --------- -- ------------------------------------------------------------------ -- -----------------------
  SEY6210      *MAT*α *leu2-3,112 ura3-52 his3-Δ200 trp1-Δ901 lys2-801 suc2-Δ9*      Robinson et al., 1988
  TDY2         SEY6210; *vam3Δ::LEU2*                                                [@B12]
  CBY31        SEY6210; *pep12Δ::HIS3*                                               [@B7]
  BWY102       SEY6210; *vps24Δ::HIS3*                                               [@B2]
  GOY8         SEY6210; *pep12Δ::LEU2 apm3Δ::HIS3*                                   Cowles et al., 1998

![Novel genetic screen to identify regions of Vam3p required for function and localization at the vacuole. (*A*) In wild-type cells, Pep12p, the endosomal t-SNARE, directs traffic from the Golgi complex to the endosome through the CPY pathway. Vam3p, the vacuolar t-SNARE, is transported through the AP-3--dependent ALP pathway to the vacuole where it functions to receive incoming vesicular traffic from both the ALP and CPY pathways. We designed a G418-based selection scheme to identify *VAM3* mutants that were able to compensate for the loss of *PEP12* and thus identify regions of Vam3p sequence responsible for restricting Vam3p activity to the AP-3--dependent pathway. (*B*) Growth of both *pep12Δ* (CBY31) cells alone or *pep12Δ* (CBY31) cells expressing *VAM3* from a single-copy plasmid (pVAM3.414) is compromised at concentrations of 50 μg/ml G418, while growth on media containing no G418 is normal. However, *pep12Δ* (CBY31) cells either overexpressing *VAM3* from a 2μ plasmid (pVAM3.424) or expressing a mutant derived from the screen, *vam3* ^L160P^, on a single-copy plasmid (pVAM3L160P.414) results in growth at 50 μg/ml G418, as well as on media containing no G418.](JCB9805091.f1){#F1}

![Vam3p mutants define a di-leucine sorting signal. Vam3 protein domain structure is shown including the extreme COOH-terminal transmembrane domain and the two coiled-coil domains. The location of the region containing the mutations recovered from the G418 resistance screen is denoted by the dashed box. The wild-type sequence at the mutated region is shown in detail. Single mutations that were recovered from the G418 resistance screen are indicated in capital letters designating the amino acid changes. The glutamine 156 to leucine mutation was not recovered in the screen but was made by site-directed mutagenesis. The level of G418 resistance conferred by each of the mutants is as follows: ++, wild-type growth; +, slower growth to single colonies; and −, no growth.](JCB9805091.f2){#F2}

![CPY sorting of *vam3* mutants in both *pep12Δ* and *vam3Δ* mutant cells. (*A*) *pep12Δ* (CBY31) cells and *pep12Δaps3Δ* (GOY8) double-mutant cells transformed with a single-copy plasmid containing wild-type *VAM3* (pVAM3.414), and *pep12Δ* (CBY31) cells transformed with vector (pRS414), *vam3* ^L160P^ or *vam3* ^N154I^ mutant isolates (pVAM3L160P. 414 and pVAM3N154I.414, respectively) were spheroplasted, and then metabolically labeled and chased for 45 min. (*B*) *vam3Δ* (TDY2) cells were transformed with the identical plasmids from *A* and were labeled and chased as whole cells for 30 min. CPY was immunoprecipitated and examined by autoradiography. For both *A* and *B*, mature and Golgi-modified precursor CPY are indicated as mCPY and p2CPY, respectively. In *A*, the percent of mature CPY is denoted beneath each individual lane.](JCB9805091.f3){#F3}

![Localization of Vam3 mutant proteins. Cleared cell lysates generated from *vam3Δ* (TDY2) cells containing either wild-type *VAM3* (pVAM3.414) or the *vam3* ^L160P^ mutant (pVAM3L160P.414) were loaded onto the top of an Accudenz step gradient and centrifuged to equilibrium. Fractions *1--12* were collected from the top of the gradient. Proteins were precipitated from the fractions and then separated by SDS-PAGE and transferred to nitrocellulose. Vam3p, Vph1p, and Pep12p were detected by immunoblotting and visualized by ECL fluorography. The distribution of both wild-type and mutant (*Vam3p^L160P^*) Vam3p and Vph1p are shown graphically in *A* and the colocalization of Vam3p^L160P^ and Pep12p are shown in *B*.](JCB9805091.f4){#F4}

![Localization of Vam3 mutant proteins in *vps24Δ* cells. *vam3Δ* (TDY2) and *vps24Δ* (BW102) cells were transformed with plasmids containing both wild-type (pGFPVAM3.426) and mutant (pGFPVAM3L160P.426) GFP-Vam3 fusion proteins. These strains were grown in selective media to exponential phase, harvested, and then resuspended in YNB for examination by microscopy. *vps24Δ* cultures were further labeled with 16 μM FM4-64 for a period of 1 h at 26°C in YPD. Labeled cells were then harvested, resuspended in YPD, and then chased for 1.5 h. After chase, cells were examined by Nomarski and fluorescence/ confocal microscopy for both GFP and FM4-64 fluorescence. Arrows in *A* indicate vacuoles and in *B* indicate class E compartments.](JCB9805091.f5){#F5}

![Vam3p di-leucine sequence alignment with putative AP-3 cargoes. The Vam3p di-leucine sequence shares significant sequence similarity to di-leucine sequences in both lysosomal and melanosomal proteins. The consensus motif (*\*Ex\*xLL*) is derived from mutagenesis data. An asterisk denotes a bias toward charged, polar amino acids, while *x* can be any amino acid. Residues that were mutated in the Vam3p sequence and are also conserved in other cargo proteins are indicated by shaded regions. ALP shares sequence similarity with Vam3p at every base that was recovered in our Vam3p mutagenesis. The acidic amino acid at −4, the polar amino acids at −5 and −3, and the proline at −1 as well as the di-leucine sequence, are conserved in the majority of the proteins that have been defined as potential AP-3 cargoes.](JCB9805091.f6){#F6}
